ACADIA Pharmaceuticals Inc. (ACAD)

46.75
0.06 0.13
NASDAQ : Health Technology
Prev Close 46.81
Open 46.41
Day Low/High 45.50 / 47.14
52 Wk Low/High 14.01 / 47.79
Volume 1.76M
Avg Volume 2.07M
Exchange NASDAQ
Shares Outstanding 154.03M
Market Cap 6.94B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Stock To Watch: ACADIA Pharmaceuticals (ACAD) In Perilous Reversal

Stock To Watch: ACADIA Pharmaceuticals (ACAD) In Perilous Reversal

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "perilous reversal" (up big yesterday but down big today) candidate

Market News: ACADIA, Escalera Resources, Urban Outfitters

Market News: ACADIA, Escalera Resources, Urban Outfitters

The stock markets in the United States declined today. Investors are becoming increasingly concern regarding the possibility that the Federal Reserve is close to making a decision to increase interest...

'Mad Money' Lightning Round: Allegiant Travel Good, Spirit Airlines Better

'Mad Money' Lightning Round: Allegiant Travel Good, Spirit Airlines Better

Cramer said Acadia Pharmaceuticals is good but speculative and he's ringing the register on Aruba Networks.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

What doesn't kill this market makes it stronger, Cramer says. His game plan includes Netflix, Berkshire Hathaway and Costco, among others.

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2014 Financial Results On February 26, 2015

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2014 Financial Results On February 26, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

Cushman & Wakefield: REITs Will Continue to Rock in 2015 – And Which Ones to Buy

Cushman & Wakefield: REITs Will Continue to Rock in 2015 – And Which Ones to Buy

In 2014, REITs outperformed the stock market. Cushman & Wakefield investment sales chairman analyzes the market and offers REITs to watch in 2015.

ACADIA Pharmaceuticals (ACAD) Highlighted As Weak On High Volume

ACADIA Pharmaceuticals (ACAD) Highlighted As Weak On High Volume

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a weak on high relative volume candidate

Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1

Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

ACADIA Pharmaceuticals To Present At The 33rd Annual J.P. Morgan Healthcare Conference On January 13, 2015

ACADIA Pharmaceuticals To Present At The 33rd Annual J.P. Morgan Healthcare Conference On January 13, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)

Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate

ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today

ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

'Mad Money' Lightning Round: I Think You Should Buy, Buy, Buy Twitter

'Mad Money' Lightning Round: I Think You Should Buy, Buy, Buy Twitter

Cramer likes Acadia Pharmaceuticals and TrueCar but is avoiding Agrium.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.

ACADIA Pharmaceuticals Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson's Disease And Related Disorders

ACADIA Pharmaceuticals Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson's Disease And Related Disorders

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase III program with NUPLAZID™ (pimavanserin) for Parkinson's disease psychosis (PDP) at the 10 th...

ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced...

ACADIA Pharmaceuticals To Present At Jefferies 2014 Global Healthcare Conference On November 20, 2014

ACADIA Pharmaceuticals To Present At Jefferies 2014 Global Healthcare Conference On November 20, 2014

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central ...

ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results And Updates Timing Of NUPLAZID™ NDA Submission

ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results And Updates Timing Of NUPLAZID™ NDA Submission

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central ...

'Mad Money' Lightning Round: Buy, Buy, Buy Lockheed Martin

'Mad Money' Lightning Round: Buy, Buy, Buy Lockheed Martin

Cramer says Leucadia National is too dangerous for him, hold on to General Electric but wait on ConocoPhillips and Hess.

Jim Cramer's 'Mad Money' Recap: Why Are Money Managers Making Things So Complicated?

Jim Cramer's 'Mad Money' Recap: Why Are Money Managers Making Things So Complicated?

The smart money is buying, not selling, on the current low oil prices, Cramer insists.

ACADIA Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 10, 2014

ACADIA Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 10, 2014

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central ...

Jim Cramer's Top Stock Picks: TWTR TASR ACAD ISIS RH

Jim Cramer's Top Stock Picks: TWTR TASR ACAD ISIS RH

Arcadia Pharmaceuticals and Isis Pharmaceuticals are the next big biotech takeover targets, Cramer says.

Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts

Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts

As long as it's here, good things are happening every day, Cramer says.

ACADIA Pharmaceuticals (ACAD) Is Strong On High Volume Today

ACADIA Pharmaceuticals (ACAD) Is Strong On High Volume Today

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

Why ACADIA Pharmaceuticals (ACAD) Stock Is Spiking Today

Why ACADIA Pharmaceuticals (ACAD) Stock Is Spiking Today

ACADIA Pharmaceuticals (ACAD) shares are up double digits on Tuesday after its Parkinson's disease treatment was designated as a Breakthrough Therapy by the FDA

Compuware Climbs on Buyout Announcement

Compuware Climbs on Buyout Announcement

Compuware Corporation (NASDAQ:CPWR), Norwegian Cruise Line Holdings Ltd (NASDAQ:NCLH) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) are among today's top gainers on the stock market midday. Postin...

ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation For NUPLAZID™ (Pimavanserin) For Parkinson’s Disease Psychosis

ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation For NUPLAZID™ (Pimavanserin) For Parkinson’s Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central ...

ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ For Pimavanserin

ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ For Pimavanserin

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central ...

ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central ...

TheStreet Quant Rating: D (Sell)